Johnson & Johnson $JNJ Stock Position Reduced by Ellevest Inc.

Ellevest Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 22.4% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,385 shares of the company’s stock after selling 400 shares during the quarter. Ellevest Inc.’s holdings in Johnson & Johnson were worth $212,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the stock. Jacobson & Schmitt Advisors LLC acquired a new stake in Johnson & Johnson during the second quarter valued at $411,000. NewSquare Capital LLC raised its stake in shares of Johnson & Johnson by 51.4% during the 2nd quarter. NewSquare Capital LLC now owns 1,611 shares of the company’s stock worth $246,000 after purchasing an additional 547 shares in the last quarter. Rockline Wealth Management LLC lifted its holdings in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Rockline Wealth Management LLC now owns 31,504 shares of the company’s stock valued at $4,812,000 after buying an additional 400 shares during the last quarter. J. W. Coons Advisors LLC grew its stake in shares of Johnson & Johnson by 1.3% in the 2nd quarter. J. W. Coons Advisors LLC now owns 23,417 shares of the company’s stock valued at $3,577,000 after buying an additional 300 shares in the last quarter. Finally, McGinn Penninger Investment Management Inc. increased its holdings in Johnson & Johnson by 0.3% in the second quarter. McGinn Penninger Investment Management Inc. now owns 28,104 shares of the company’s stock worth $4,293,000 after buying an additional 72 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $186.50 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $194.48. The company has a market cap of $449.34 billion, a P/E ratio of 18.00, a P/E/G ratio of 2.19 and a beta of 0.38. The business’s 50 day moving average is $184.25 and its two-hundred day moving average is $168.63. The company has a quick ratio of 0.80, a current ratio of 1.07 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The company had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be paid a $1.30 dividend. This represents a $5.20 annualized dividend and a dividend yield of 2.8%. The ex-dividend date is Tuesday, November 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Wall Street Analysts Forecast Growth

Several analysts have commented on the stock. The Goldman Sachs Group boosted their target price on shares of Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday, October 9th. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective for the company in a report on Monday, October 20th. Johnson Rice set a $190.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research report on Wednesday, October 22nd. Guggenheim raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their price target for the stock from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Finally, JPMorgan Chase & Co. increased their price objective on Johnson & Johnson from $185.00 to $200.00 and gave the company a “neutral” rating in a report on Tuesday, September 16th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and a consensus price target of $199.05.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.